Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RENVELA 2.4 g powder for oral suspension - SFDA Drug Approval Details

Approvals/SFDA/RENVELA 2.4 g powder for oral suspension

Authorized

NCE

RENVELA 2.4 g powder for oral suspension

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: dcbea30ead94ef6b
Company: Unknown
Type: NCE

Approval Details

Approval Id: dcbea30ead94ef6b
Drug Approval Sfda Name: RENVELA 2.4 g powder for oral suspension
Trade Name: RENVELA 2.4 g powder for oral suspension
Generic Name: SEVELAMER CARBONATE
Register Number: 4-832-15
Register Year: 2015
Drug Type: NCE
Route Of Administration: Oral use
Package Type: Sachet
Package Size: 60
Size Unit: g
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: store below 25°c
Shelf Life: 36 Months
Distribution Site: Pharmacy
Description Code: 7000002616-2.4-100000073649
Price: 623.25

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

dcbea30ead94ef6b

Type

NCE

Back to SFDA Approvals